Login / Signup

Efficacy and safety of autologous haematopoietic stem cell transplantation versus alemtuzumab, ocrelizumab, ofatumumab or cladribine in relapsing remitting multiple sclerosis (StarMS): protocol for a randomised controlled trial.

Gavin BrittainJennifer PetrieKate E M DuffyRachel GloverKatie HullockDiana PapaioannouElisa RoldánColette BeecherMatthew BursnallOlga CiccarelliAlasdair J ColesCindy CooperGavin GiovannoniIan GabrielMajid KazmiCharalampia KyriakouRichard NicholasDavid PalingAndy PeniketNeil ScoldingEli SilberThushan I de SilvaAnnalena VenneriStephen J WaltersCarolyn Anne YoungPaolo A MuraroBasil SharrackJohn A Snowdennull null
Published in: BMJ open (2024)
ISRCTN88667898.
Keyphrases
  • multiple sclerosis
  • stem cell transplantation
  • high dose
  • white matter
  • randomized controlled trial
  • bone marrow
  • cell therapy
  • low dose
  • rheumatoid arthritis